In a large cohort of early-stage HCC patients receiving an array of approved first cycle LDT options, we showed AFP-L3 and DCP expression in combination with AFP was associated with a dismal LDT response and an accelerated 6-month median time to progression resulting in dismal 1-year progression rates [12, 17]. The gene discussed is ACE; the disease is hepatocellular carcinoma.